Efficacy
ALK-ALCL, Tumor, ENKTL
TUMOR
In total of 20 patients, 14 paitents were evaluable for efficacy, and the median treatment cycle of the combined regimen was 7 (range 2 to 21). For all patients, the ORR was 30% (6/20) (95% CI, 11.9% to 54.3%), with two patients (10%) achieving CR (one patient with ENKTL and the other with ALK-ALCL). The median DoR was not reached (NR) (range: 3.6 months to NR) (Tumor response of all patients.NR, not reached; CI, confidence interval.Tumor response in evaluable patients (n=14). After a median follow-up of 27.2 months (range: 0.5 to 39.9 months), 11 (55%) of 20 patients died. The median PFS for all patients was 5.6 months (95% CI, 1.8 to NR) (Kaplan-Meier curve of 